Synklino

Lyngby, Denmark

Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection.

$32.0M raised

Jun 2022

Series A

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Synklino raised?

Synklino has raised $32.0M in total funding. The most recent round was Series A. The last funding was announced in June 2022.

Who are Synklino's investors?

Synklino's investors include BioInnovation Institute, Maj Invest Equity, EIR Ventures, Vaekstfonden, PKA.

Where is Synklino headquartered?

Synklino is headquartered in Lyngby, Denmark.

What does Synklino do?

Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection.

What stage is Synklino at?

Synklino is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated June 8, 2022.

MLA

"Synklino — Funding & Investors." VCBacked, June 8, 2022, https://www.vcbacked.co/company/synklino. Accessed July 2, 2026.

APA

VCBacked. (2022). Synklino — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/synklino

Wikipedia (cite web)

{{cite web |title=Synklino — Funding & Investors |url=https://www.vcbacked.co/company/synklino |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated June 8, 2022.